Mitoxantrone intermediate-dose cytarabine effective tolerable regimen treatment refractory acute myeloid leukemia Thirty-two patients refractory acute myeloid leukemia AML salvage therapy single course mitoxantrone intravenous IV bolus IV period hour cytarabine Ara-C IV period hours days MEC Eighteen patients resistant conventional daunorubicin Ara-C induction treatment patients months initial remission patients bone marrow transplantation BMT procedure Overall patients complete remission CR infection induction resistant disease Age years factor predictive response rate median remission duration weeks overall median survival weeks Severe myelosuppression patients fever infections patients Nonhematologic toxicity minimal MEC regimen significant antileukemic activity acceptable toxicity salvage AML benefit front-line AML therapy 